임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
40건 표시
- 3상모집 중· Alzheimer DiseaseA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
리드: 일라이 릴리
- 3상모집 중· Alzheimer DiseaseDonanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
리드: 일라이 릴리
- 3상모집 중· Sleep Apnea, ObstructiveA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
리드: 일라이 릴리
- 3상모집 중· Depressive Disorder, MajorA Study of Brenipatide in Adult Participants With Major Depressive Disorder
리드: 일라이 릴리
- 3상모집 중· Diabetes Mellitus, Type 1A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
리드: 일라이 릴리
- 3상모집 중· Diabetes Mellitus, Type 1A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
리드: 일라이 릴리
- 3상모집 중· Breast NeoplasmsA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
리드: 일라이 릴리 · 협력: 화이자
- 3상모집 중· Polymyalgia Rheumatica (PMR)Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
협력: 일라이 릴리
- 3상모집 중· Carcinoma, Transitional CellA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
리드: 일라이 릴리
- 3상모집 중· Atherosclerosis Cardiovascular DiseaseA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
리드: 일라이 릴리
- 3상모집 중· Peripheral Arterial DiseaseEfficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
리드: 일라이 릴리
- 3상모집 중· Alcohol Use DisorderA Study of Brenipatide in Participants With Alcohol Use Disorder
리드: 일라이 릴리
- 3상모집 중· Metabolic Dysfunction-Associated Steatotic Liver DiseaseA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
리드: 일라이 릴리
- 3상모집 중· Alcohol Use DisorderA Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
리드: 일라이 릴리
- 3상모집 중· Urinary Incontinence,StressA Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
리드: 일라이 릴리
- 3상모집 중· Elevated Lp(a)Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
리드: 일라이 릴리
- 3상모집 중· Carcinoma, Non-Small-Cell LungStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
리드: 일라이 릴리 · 협력: 아스트라제네카
- 3상모집 중· ObesityA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
리드: 일라이 릴리
- 3상모집 중· Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
리드: 일라이 릴리
- 3상모집 중· Perennial Allergic Rhinitis (PAR)A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
리드: 일라이 릴리
- 3상모집 중· Crohn's DiseaseA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
리드: 일라이 릴리
- 3상모집 중· Carcinoma, Non-Small-Cell LungA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
리드: 일라이 릴리
- 3상모집 중· Areata AlopeciaA Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
리드: 일라이 릴리
- 3상모집 중· Chronic Lymphocytic LeukemiaA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
협력: 일라이 릴리
- 3상모집 중· Juvenile Idiopathic ArthritisA Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
리드: 일라이 릴리
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.